First Tracks Biotherapeutics Inc
TRAX | NASDAQ
$45.08
-$0.15 (-0.32%)
At close: Oct 30, 2026, 4:00 PM ET
$45.56
+$0.48 (+1.06%)
Pre-market:
Nov 2, 2026, 3:40 AM ET
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q1 2025 Mar 31, 2025 |
|---|---|---|---|
Revenue | n/a | n/a | n/a |
Cost of Revenue | 207K | n/a | n/a |
Gross Profit | -207K | n/a | n/a |
Operating Income | -87.75M | -52.81M | -51.28M |
Interest Income | 3.89M | 2.33M | 4.09M |
Pretax Income | -83.86M | -50.48M | -47.2M |
Net Income | -83.86M | -50.48M | -47.2M |
Selling & General & Admin | 28.05M | 18.86M | 9.82M |
Research & Development | 59.49M | 33.96M | 41.47M |
Other Expenses | n/a | n/a | n/a |
Operating Expenses | 87.54M | 52.81M | 51.28M |
Interest Expense | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 87.75M | 52.81M | 51.28M |
Income Tax Expense | n/a | n/a | n/a |
Shares Outstanding (Basic) | 35.39M | 34.75M | 34.75M |
Shares Outstanding (Diluted) | 35.39M | 34.75M | 34.75M |
EPS (Basic) | -2.39 | -1.45 | -1.36 |
EPS (Diluted) | -2.39 | -1.45 | -1.36 |
EBITDA | -87.42M | -52.69M | -50.67M |
EBIT | -87.75M | -52.81M | -51.28M |
Depreciation & Amortization | 332K | 125K | 606K |
Add to Watchlist
Select watchlists to add or remove TRAX